Private Management Group Inc. Lowers Stake in Elanco Animal Health Incorporated $ELAN

Posted by Francis Steltz on Aug 30th, 2026

Private Management Group Inc. trimmed its holdings in Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 17.1% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 678,317 shares of the company’s stock after selling 139,802 shares during the period. Private Management Group Inc. owned 0.14% of Elanco Animal Health worth $16,693,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in ELAN. NewEdge Advisors LLC raised its stake in Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after acquiring an additional 627 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Elanco Animal Health during the 2nd quarter worth approximately $38,000. Root Financial Partners LLC grew its stake in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after purchasing an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. purchased a new position in shares of Elanco Animal Health in the 4th quarter valued at approximately $41,000. Finally, Bessemer Group Inc. increased its holdings in shares of Elanco Animal Health by 33.2% in the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock valued at $50,000 after purchasing an additional 525 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Price Performance

Elanco Animal Health stock opened at $24.16 on Friday. The company has a market cap of $12.07 billion, a P/E ratio of -58.93, a price-to-earnings-growth ratio of 1.44 and a beta of 1.67. Elanco Animal Health Incorporated has a one year low of $17.11 and a one year high of $27.98. The business has a fifty day moving average of $24.62 and a two-hundred day moving average of $24.01. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.31 billion. During the same period in the prior year, the company posted $0.26 EPS. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, analysts predict that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Citigroup increased their price target on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. TD Cowen upped their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Finally, Weiss Ratings downgraded shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Elanco Animal Health has an average rating of “Moderate Buy” and an average price target of $29.09.

View Our Latest Research Report on Elanco Animal Health

Insider Buying and Selling at Elanco Animal Health

In other news, Director Michael J. Harrington purchased 5,000 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were acquired at an average price of $21.82 per share, for a total transaction of $109,100.00. Following the acquisition, the director directly owned 131,451 shares in the company, valued at approximately $2,868,260.82. The trade was a 3.95% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Shiv O’neill acquired 3,998 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, August 18th. The shares were purchased at an average cost of $23.58 per share, with a total value of $94,272.84. Following the completion of the acquisition, the insider owned 87,832 shares of the company’s stock, valued at $2,071,078.56. The trade was a 4.77% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 63,198 shares of company stock worth $1,473,109. Corporate insiders own 1.14% of the company’s stock.

Elanco Animal Health Company Profile

(Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.